Jiangsu Nhwa Pharmaceutical Co., LTD (SHE:002262)
22.68
+0.36 (1.61%)
Apr 1, 2025, 2:45 PM CST
SHE:002262 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
Operating Revenue | 5,638 | 4,976 | 4,255 | 3,919 | 3,344 | Upgrade
|
Other Revenue | 59.61 | 65.63 | 43.49 | 16.53 | 16.99 | Upgrade
|
Revenue | 5,698 | 5,042 | 4,299 | 3,936 | 3,361 | Upgrade
|
Revenue Growth (YoY) | 13.01% | 17.29% | 9.22% | 17.09% | -18.99% | Upgrade
|
Cost of Revenue | 1,546 | 1,403 | 1,037 | 932.68 | 843.14 | Upgrade
|
Gross Profit | 4,152 | 3,638 | 3,262 | 3,003 | 2,518 | Upgrade
|
Selling, General & Admin | 2,244 | 1,944 | 1,847 | 1,743 | 1,443 | Upgrade
|
Research & Development | 595.65 | 549.32 | 454.25 | 351.73 | 245.86 | Upgrade
|
Other Operating Expenses | 65.65 | 60.2 | 57.46 | 54.04 | 45.61 | Upgrade
|
Operating Expenses | 2,939 | 2,569 | 2,360 | 2,156 | 1,737 | Upgrade
|
Operating Income | 1,213 | 1,070 | 901.63 | 847.28 | 781.53 | Upgrade
|
Interest Expense | -4.03 | -4.16 | -4.95 | -5.06 | -1.59 | Upgrade
|
Interest & Investment Income | 87.82 | 74.85 | 61.8 | 53.92 | 48.32 | Upgrade
|
Currency Exchange Gain (Loss) | 0.17 | 0.41 | 0.91 | -1.14 | -0.38 | Upgrade
|
Other Non Operating Income (Expenses) | -1.9 | -0.74 | -3.19 | -1.62 | 1.43 | Upgrade
|
EBT Excluding Unusual Items | 1,295 | 1,140 | 956.2 | 893.38 | 829.31 | Upgrade
|
Impairment of Goodwill | - | - | - | - | -0.82 | Upgrade
|
Gain (Loss) on Sale of Assets | 0.29 | 0.15 | 0.37 | -0.24 | -0.15 | Upgrade
|
Asset Writedown | 0.07 | 0.22 | -0.28 | -0.74 | -0.21 | Upgrade
|
Other Unusual Items | 0.99 | 28.32 | 33.62 | 23.38 | 22.35 | Upgrade
|
Pretax Income | 1,297 | 1,169 | 989.91 | 915.78 | 850.48 | Upgrade
|
Income Tax Expense | 155.9 | 134.4 | 109.82 | 117.75 | 123.37 | Upgrade
|
Earnings From Continuing Operations | 1,141 | 1,034 | 880.09 | 798.02 | 727.1 | Upgrade
|
Minority Interest in Earnings | 2.77 | 2.67 | 20.62 | -0.24 | 1.72 | Upgrade
|
Net Income | 1,144 | 1,037 | 900.71 | 797.78 | 728.82 | Upgrade
|
Net Income to Common | 1,144 | 1,037 | 900.71 | 797.78 | 728.82 | Upgrade
|
Net Income Growth | 10.29% | 15.12% | 12.90% | 9.46% | 9.88% | Upgrade
|
Shares Outstanding (Basic) | 1,012 | 1,007 | 1,012 | 1,010 | 1,012 | Upgrade
|
Shares Outstanding (Diluted) | 1,012 | 1,007 | 1,012 | 1,010 | 1,012 | Upgrade
|
Shares Change (YoY) | 0.53% | -0.53% | 0.22% | -0.24% | 0.72% | Upgrade
|
EPS (Basic) | 1.13 | 1.03 | 0.89 | 0.79 | 0.72 | Upgrade
|
EPS (Diluted) | 1.13 | 1.03 | 0.89 | 0.79 | 0.72 | Upgrade
|
EPS Growth | 9.71% | 15.73% | 12.66% | 9.72% | 9.09% | Upgrade
|
Free Cash Flow | 466.07 | 634.31 | 533.27 | 495.01 | 979.74 | Upgrade
|
Free Cash Flow Per Share | 0.46 | 0.63 | 0.53 | 0.49 | 0.97 | Upgrade
|
Dividend Per Share | 0.360 | 0.320 | 0.200 | 0.200 | 0.100 | Upgrade
|
Dividend Growth | 12.50% | 60.00% | - | 100.00% | - | Upgrade
|
Gross Margin | 72.87% | 72.17% | 75.88% | 76.30% | 74.92% | Upgrade
|
Operating Margin | 21.29% | 21.22% | 20.97% | 21.53% | 23.25% | Upgrade
|
Profit Margin | 20.07% | 20.57% | 20.95% | 20.27% | 21.68% | Upgrade
|
Free Cash Flow Margin | 8.18% | 12.58% | 12.41% | 12.58% | 29.15% | Upgrade
|
EBITDA | 1,364 | 1,205 | 1,025 | 959.57 | 878.36 | Upgrade
|
EBITDA Margin | 23.95% | 23.90% | 23.84% | 24.38% | 26.13% | Upgrade
|
D&A For EBITDA | 151.16 | 135.14 | 123.12 | 112.28 | 96.83 | Upgrade
|
EBIT | 1,213 | 1,070 | 901.63 | 847.28 | 781.53 | Upgrade
|
EBIT Margin | 21.29% | 21.22% | 20.97% | 21.53% | 23.25% | Upgrade
|
Effective Tax Rate | 12.02% | 11.50% | 11.09% | 12.86% | 14.51% | Upgrade
|
Revenue as Reported | 5,698 | 5,042 | 4,299 | 3,936 | 3,361 | Upgrade
|
Updated Oct 25, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.